June 30, 2021

Eli Casdin Chief Executive Officer CM Life Sciences, Inc. c/o Corvex Management LP 667 Madison Avenue New York, New York 10065

Re: CM Life Sciences,

Preliminary Proxy Statement on Schedule PREM14A

Filed June 28, 2021 File No. 001-39482

Amendment No. 2 to

Dear Mr. Casdin:

We have reviewed your

amended filing and have the following comment.

 $\hbox{ Please respond to this comment within ten business days by providing the requested } \\$ 

information or advise us as soon as possible when you will respond. If you do not believe our

comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to this comment, we may have additional comments.

Amendment No. 2 to Preliminary Proxy Statement on Schedule PREM14A Related Agreements, page 31

We note your disclosure in this section that the summary disclosure of the Related Agreements is qualified in its entirety by reference to the complete text of each of the Related Agreements and that the forms of the Forfeiture Agreement, Shareholder Lock-up Letter, Sponsor Support Agreement, and Subscription Agreement are attached hereto as Annexes C, D, and E, respectively. However, we do not see that you have included the Forfeiture Agreement, Shareholder Lock-up Letter and Sponsor Support Agreement as annexes in your preliminary proxy statement. Please include those agreements as annexes to your proxy statement and revise this section to refer to the correct annexes, or revise your disclosure as appropriate.

We remind you that the company and its management are responsible for the accuracy

and adequacy of their disclosures, notwithstanding any review, comments, action or absence of

action by the staff.

Eli Casdin

CM Life Sciences, Inc.

June 30, 2021

Page 2

You may contact Jenn Do at 202-551-3743 or Terence O'Brien at 202-551-3355 if you have questions regarding comments on the financial statements and rel

have questions regarding comments on the financial statements and related matters. Please  $\,$ 

contact Ada D. Sarmento at 202-551-3798 or Tim Buchmiller at 202-551-3635 with any other questions.

Sincerely,

Finance Comapany NameCM Life Sciences, Inc.

June 30, 2021 Page 2 cc: Colin J. Diamond, Esq. FirstName LastName

Office of Life Sciences

Division of Corporation